LONDON: RTW Biotech Opportunities Ltd., a London-listed investment company, announced Wednesday that its portfolio company, Evommune Inc., has completed a $150 million initial public offering on the New York Stock Exchange. The clinical-stage biotechnology company, which is developing therapies for chronic inflammatory diseases, priced its IPO at $16 per share, selling 9.4 million shares. Evommune…
LONDON: RTW Biotech Opportunities Ltd, a London Stock Exchange-listed investment company focusing on high-growth potential assets in the life sciences sector, has announced a new investment in Alesta Therapeutics. The Netherlands-based biotechnology firm, Alesta, is dedicated to developing novel oral small molecule therapies for rare, underserved diseases. Alesta Therapeutics recently completed a €65 million (US$67…
LONDON: RTW Biotech Opportunities Ltd, a London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, announced investments in new private portfolio companies, Mirador Therapeutics and Santa Ana Bio. RTW, alongside other investment vehicles managed by RTW Investments, LP, participated in Mirador’s Series A financing round…
LONDON: RTW Biotech Opportunities Ltd, a London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, noted the announcement by portfolio company, Lycia Therapeutics, of its completion of a $106.6 million Series C financing round. The company, alongside other investment vehicles managed by RTW Investments, LP…